| Autor: |
Suresh, Pratheksha, Murthannagari, Vivek Reddy, Krishnan, Ganesh Gonna Nandhi, Shivashankar, Neerej, Mullaiventhan, Tholkapiyan |
| Předmět: |
|
| Zdroj: |
International Journal of Pharmaceutical Investigation; Jul-Sep2024, Vol. 14 Issue 3, p607-615, 9p |
| Abstrakt: |
Historically, there have been constraints on pediatric drug trials, resulting in an absence of authorized medicines for children and a significant reliance on off-label use. Pediatric drug development is critical to addressing the special issues of treating children and adolescents. The lack of authorized pediatric treatments has led to efforts to incentivize and compel pediatric medical research in the United States and Europe. The data collected from the FDA and the EMA databases from 2013 to 2023 were analyzed. Statistical analyses revealed trends and changes in exclusive interventions, and qualitative analyses examined research methodologies specific to pediatrics. Clinical trials play a vital role in closing the knowledge gap and improving pediatric treatment. Recent advancements in technology and research methodologies have helped improve pediatric healthcare and treatment. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
